B+
Bull case
25%
Probability
Target price
$27.00
+46.3% vs current
AMPH
AmphastarDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$22.00
+19.2% vs current
B-
Bear case
30%
Probability
Target price
$16.00
-13.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+65.3
Score
AI commentary
Post-earnings tone turned cautious. The company confirmed results on May 7, 2026, and by the latest available market print on May 9, 2026 UTC, AMPH was about $19.00 versus the packet's May 7 close anchor of $24.03, a drop of roughly 21%, indicating the market focused on profit and margin deterioration rather than flat revenue. Trusted analyst rating or target revisions were not available in the checked evidence, so this remains a low-coverage monitoring situation rather than a high-conviction reset.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31eventQ1 earnings reset near-term expectations after profit and margin compressionHigh impact
First-quarter 2026 revenue was essentially flat at $171.2 million, but GAAP EPS fell to $0.14 from $0.51 and gross margin declined to 41.1% from 50.0% as lower pricing on higher-margin products and higher manufacturing costs pressured profitability; with no clear 2026 outlook in the filing set, post-print sentiment is likely to stay cautious while investors assess whether the selloff already discounts the weaker quarter [#8-K-2026-05-07] [#10-Q-2026-05-07].
2026-12-31catalystRecent launches must prove they can offset BAQSIMI and glucagon erosionHigh impact
Management highlighted approval and launch of Ipratropium Bromide HFA, while other products revenue rose 34% helped by albuterol, iron sucrose, teriparatide, and dextrose; however BAQSIMI sales fell 15% and glucagon dropped 56%, so the core debate is whether newer products can sustainably replace declining legacy profit pools [#8-K-2026-05-07].
2027-06-30catalystPipeline and licensing activity add optionality but raise execution demandsHigh impact
R&D expense increased 33% year over year, driven by insulin, inhalation, and proprietary pipeline spending, and included a $2.0 million upfront payment tied to the Hanxin licensing agreement; that supports longer-term optionality, but near-term monetization is uncertain and spend discipline matters given the weak quarter [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology